Drug · CHEMBL628
PENTOXIFYLLINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PENTOXIFYLLINE. Drugs and targets, record CHEMBL628. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL628
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- BL 191, BL-191, C04AD03, NSC-637086, NSC-758481, Oxpentifylline, Oxypentifylline, Pentoxifilina, Pentoxiphyllin
- ChEMBL
Targets25
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADORA2A | Adenosine A2 receptor | Adenosine A2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/135 |
| ADORA2B | Adenosine A2 receptor | Adenosine A2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/136 |
| PDE10A | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/10846 |
| PDE1A | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5136 |
| PDE1B | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5153 |
| PDE1C | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5137 |
| PDE2A | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5138 |
| PDE3A | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5139 |
| PDE3B | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5140 |
| PDE4A | 3',5'-cyclic phosphodiesterase | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5141 |
1 to 10 of 25Source ChEMBL
See all 25 targetsDiseases88
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| chronic kidney disease | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005300 |
| alcoholic hepatitis | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0001505 |
| metabolic dysfunction-associated steatohepatitis | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0007027 |
| cutaneous leishmaniasis | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005446 |
| HIV infectious disease | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| Infertility | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0000789 |
| anemia | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0002280 |
| diabetic kidney disease | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005016 |
| fibrosis | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=EFO_0006890 |
| major depressive disorder | Phase 1/2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0002009 |
1 to 10 of 88Source Open Targets
See all 88 diseasesTrials175
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01263925 | Prostaglandin E1 in Outpatients With Intermittent Claudication | Phase 3 | 561 | 2012-06-29 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT01382303 | Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients | Phase 4 | 174 | 2017-06-16 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT01809132 | Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis | Phase 2/3 | 104 | 2020-12-10 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT02487225 | Pentoxifylline Treatment in Acute Pancreatitis (AP) | Phase 3 | 83 | 2019-01-23 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT05284656 | Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease | Phase 3 | 80 | 2025-06-11 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT00590161 | Pentoxifylline in Patients With Nonalcoholic Steatohepatitis | Phase 2 | 55 | 2013-09-26 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT00583700 | Trental & Vitamin E for Radiation-Induced Fibrosis | Phase 2 | 54 | 2013-01-29 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT01102218 | A Safety Study of Pentoxifylline for the Treatment of Anemia | Phase 2 | 48 | 2012-03-26 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT00770328 | The Effects of Pentoxifylline on PAI-1 in an Obese Population | Phase 4 | 37 | 2017-11-30 | pentoxifylline | Its name | ClinicalTrials.gov |
| NCT01625845 | Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED) | Phase 2 | 36 | 2015-12-03 | pentoxifylline | Its name | ClinicalTrials.gov |
1 to 10 of 175
See all 175 trialsComparisons in its trials25
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pentoxifylline vs Cilostazol: deaths from any cause | 0 of 1,687 | 0 of 1,687 | 3,374 | NCT05635370 | Trial comparisons |
| Alprostadil vs Pentoxifylline: serious adverse events | 19 of 276 | 17 of 285 | 561 | NCT01263925 | Trial comparisons |
| Pentoxifylline vs Placebo: serious adverse events | 0 of 87 | 0 of 87 | 174 | NCT01382303 | Trial comparisons |
| Pentoxifylline vs Placebo: deaths from any cause | 2 of 45 | 0 of 38 | 83 | NCT02487225 | Trial comparisons |
| Pentoxifylline vs Placebo: serious adverse events | 1 of 45 | 0 of 38 | 83 | NCT02487225 | Trial comparisons |
| Pentoxifylline 400 mg PO Tid vs Placebo Tid: serious adverse events | 0 of 26 | 0 of 29 | 55 | NCT00590161 | Trial comparisons |
| Intervention: Pentoxifylline & Vitamin E vs Control Arm: serious adverse events | 0 of 27 | 0 of 27 | 54 | NCT00583700 | Trial comparisons |
| Erythropoietin Plus Pentoxifylline vs Erythropoietin Alone: serious adverse events | 12 of 24 | 12 of 24 | 48 | NCT01102218 | Trial comparisons |
| Pentoxifylline vs Placebo: serious adverse events | 0 of 22 | 0 of 15 | 37 | NCT00770328 | Trial comparisons |
| Pentoxifylline vs Placebo: Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization | 0 of 14 | 2 of 14 | 28 | NCT01292005 | Trial comparisons |
1 to 10 of 25
See all 25 comparisons in its trialsPapers from its trials92
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials6
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Trail Making Test B | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL628
GET https://conductscience.org/api/drugs/v1/CHEMBL628/targets?page=2